(Q46620650)

English

Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia

scientific article published in April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

1 reference

based on heuristic

inferred from title

Rebeca Northland

5

object named as

Rebeca Northland

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

author name string

Peter E Pertel

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Patricia Bernardo

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Charles Fogarty

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Peter Matthews

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Mark Benvenuto

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Grace M Thorne

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Steven A Luperchio

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Robert D Arbeit

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Jeff Alder

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

language of work or name

0 references

publication date

1 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

46

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

1142-1151

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1086%2F533441

21 January 2018

Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1086%2F533441

21 January 2018

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

1 reference

https://api.crossref.org/works/10.1086%2F533441

21 January 2018

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1086%2F533441

21 January 2018

STUDIES ON PNEUMONIA IN CHILDREN: I. Mortality, Blood Cultures, and Humoral Antibodies in Pneumococcus Pneumonia

1 reference

https://api.crossref.org/works/10.1086%2F533441

21 January 2018

Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study

1 reference

https://api.crossref.org/works/10.1086%2F533441

21 January 2018

Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.

1 reference

https://api.crossref.org/works/10.1086%2F533441

21 January 2018

Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1086%2F533441

21 January 2018

Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults

1 reference

https://api.crossref.org/works/10.1086%2F533441

21 January 2018

Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults

1 reference

https://api.crossref.org/works/10.1086%2F533441

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18444848

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46620650&oldid=2122655389"